Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Director | June 05, 2020 | June 09, 2020 |
| IonQ, Inc.IONQ · Entity 3350 | Director | May 26, 2022 | May 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date June 05, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2030-06-04 | Direct | 18,188 |
Reported balance
After 2020-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-05 · Grant · Acquired 18,188 · Balance 18,188 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.
IonQ, Inc.
Report date May 26, 2022 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 571,894 |
Reported balance
After 2022-05-26 transaction · row 1
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 16,210 · Balance 571,894 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2032-05-26 | Direct | 32,050 |
Reported balance
After 2022-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-26 · Grant · Acquired 32,050 · Balance 32,050 F2: The option will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
F2: The option will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2022 Filed May 27, 2022 17:19 UTC | IonQ, Inc. IONQ · Entity 3350 | GrantStock Option (right to buy) · Derivative | 32,050 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001209191-22-032655 · doc4.xml · derivative · entry 2 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,050 Underlying: Common Stock · 32,050 shares Expires 2032-05-26 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 17:19 UTC | IonQ, Inc. IONQ · Entity 3350 | GrantCommon Stock | 16,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032655 · doc4.xml · nonDerivative · entry 1 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,894 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 18:43 UTC | IonQ, Inc. IONQ · Entity 3350 | OtherCommon Stock | 125,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-025453 · doc4.xml · nonDerivative · entry 1 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,684 F1 · kind: Represents a pro rata distribution, and not a purchase of securities, from GV 2016 LP to the Reporting Person without additional consideration. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:57 UTC | IonQ, Inc. IONQ · Entity 3350 | OtherCommon Stock | 125,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024325 · doc4.xml · nonDerivative · entry 1 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,717 F1 · kind: Represents a pro rata distribution, and not a purchase of securities, from GV 2016 LP to the Reporting Person without additional consideration. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 18:13 UTC | IonQ, Inc. IONQ · Entity 3350 | GrantStock Option (right to buy) · Derivative | 8,320 | $0.00 Strike: $12.93 | $0.00 |
DisclosureSEC source: 0001209191-22-003797 · doc4.xml · derivative · entry 2 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,320 Underlying: Common Stock · 8,320 shares Expires 2032-01-14 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) the date of the 2022 Annual Meeting (or the date immediately prior to the 2022 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election), or (ii) January 14, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Director through such vesting date. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 18:13 UTC | IonQ, Inc. IONQ · Entity 3350 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003797 · doc4.xml · nonDerivative · entry 1 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,750 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2022 Annual Meeting (or the date immediately prior to the 2022 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election), or (ii) January 14, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Director through such vesting date. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:34 UTC | IonQ, Inc. IONQ · Entity 3350 | GrantCommon Stock | 300,000 | $10.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-21-059175 · doc4.xml · nonDerivative · entry 1 Byers Blake · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · shares: These shares were purchased from the Issuer in a private placement. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0000899243-20-015805 · doc4.xml · derivative · entry 1 BYERS BLAKE · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016410 · doc4.xml · derivative · entry 1 BYERS BLAKE · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:25 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries B Preferred Stock · Derivative | 8,494,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018319 · doc4.xml · derivative · entry 3 BYERS BLAKE · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,287,511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F1 · price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:25 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries A Preferred Stock · Derivative | 133,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018319 · doc4.xml · derivative · entry 2 BYERS BLAKE · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 51,626 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F1 · price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:25 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 3,339,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018319 · doc4.xml · nonDerivative · entry 1 BYERS BLAKE · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,339,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.